Approval · Notice of Compliance 21317 · 2018
KUVAN: Notice of Compliance 21317
Issued September 14, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21317
- Date
- September 14, 2018
- Company
- Biomarin Pharmaceutical IncNovato, California, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revision to inner/outer labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KUVAN | Not yet assigned | — |
Medicinal ingredients
- SAPROPTERIN DIHYDROCHLORIDE 100 MG per TAB